Graft Versus Host Disease

Graft versus host disease (GVHD) is a complication that can develop after a person has had a bone marrow or stem cell transplant. In the disease, the host body comes under attack from the donated cells.

What is Graft Versus Host Disease (GVHD)?

Types of Graft Versus Host Disease (GVHD)

Symptoms and Diagnosis of Graft Versus Host Disease (GVHD)

Treatment of Graft Versus Host Disease (GVHD)

Causes and Risk Factors of Graft Versus Host Disease (GVHD)

Preventing Graft Versus Host Disease (GVHD)

Research into Graft Versus Host Disease (GVHD)

Graft Versus Host Disease Research

Latest Graft Versus Host Disease News and Research

'Humanized' mouse model beats current approaches for finding the best organ donor

A "humanized" mouse model equipped with the immune system of a patient who needs an organ transplant beats current measures for identifying the best potential living donor, scientists report.

27 Aug 2021

Researchers conduct first-in-man clinical trial for new stem cell technology

Institutes and centres under the SingHealth Duke-NUS Academic Medical Centre (AMC) are joining hands together with Singapore's first private cord blood bank, Cordlife Group Limited (Cordlife), to test a novel technology that expands the number of blood-forming stem cells from stored umbilical cord blood (UCB) in a first-in-man study in Singapore.

12 May 2021

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma.

30 Apr 2021

Researchers develop an effective strategy to fight against chronic myelomonocytic leukemia

Leukemias are debilitating cancers of the hematopoietic or blood-forming cells of the bone marrow. Now, researchers at Tokyo Medical and Dental University describe an ingenious strategy against chronic myelomonocytic leukemia (CMML) wherein an antibody-drug conjugate (ADC) comprising a cytotoxic drug payload linked to an antibody that selectively targets specific cell lines effectively blocks malignant cell proliferation at source.

16 Apr 2021

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Immune mechanism responsible for adverse inflammatory reactions after stem cell transplant identified

In the treatment of leukemia, stem cell transplantation subsequent to chemotherapy and radiation can often engender severe adverse inflammatory reactions - especially in the skin or in the gut, since these so-called barrier organs are more frequently affected.

19 Nov 2020

New Independent Research Organization status awarded to Anthony Nolan and ANRI

Anthony Nolan and the Anthony Nolan Research Institute have a long tradition of supporting and engaging with researchers.

9 Nov 2020

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

Today, the U.S. Food and Drug Administration announced that it has awarded six new clinical trial research grants to principal investigators from academia and industry totaling over $16 million over the next four years.

8 Oct 2020

Umbilical cord blood safely and effectively treats children with rare genetic disorders

Researchers at UPMC Children's Hospital of Pittsburgh found that infusing umbilical cord blood - a readily available source of stem cells - safely and effectively treated 44 children born with various non-cancerous genetic disorders, including sickle cell, thalassemia, Hunter syndrome, Krabbe disease, metachromatic leukodystrophy (MLD) and an array of immune deficiencies.

14 Jul 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Dana-Farber launches clinical test of blood cancer drug in COVID-19 patients

Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus. T

20 May 2020

Harmful genetic mutations in healthy donors' stem cells may create problems in AML patients

A stem cell transplant - also called a bone marrow transplant - is a common treatment for blood cancers, such as acute myeloid leukemia.

16 Jan 2020

Temperature fluctuations could give early indications of graft-versus-host disease

By continuously monitoring the body temperature of mice that had undergone bone-marrow transplants, researchers were able to detect early warning signs of graft-versus-host disease - a dangerous, sometimes deadly response of the transplanted immune system - in a simple, non-invasive way.

6 Jan 2020

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma, easing concerns that these patients are at heightened risk for severe immune-related complications.

9 Dec 2019

Adding venetoclax to transplant conditioning regimen shows promise in patients with myeloid cancers

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

8 Dec 2019

Adding post-transplant chemotherapy to standard treatment improves remission of allogeneic transplant patients

Investigators in the Blood and Marrow Transplant Program at Rutgers Cancer Institute of New Jersey compared outcomes for patients having undergone allogeneic stem cell transplant when post-transplant cyclophosphamide (PCy, a type of chemotherapy) was added as part of standard treatment to prevent disease through an immune response (immunoprophylaxis) than if this standard treatment was given alone.

5 Dec 2019

A major step toward preventing GvHD in patients receiving bone marrow transplants

A drug used for rheumatoid arthritis has moved a step closer to FDA approval for a desperately needed new use.

4 Dec 2019

New stem cell technology gives new hope for high-risk leukemia patients

Few people get a second chance at life. And fewer still are forced to take it before their 25th birthday. Tyler Rabey is one of those people. He was diagnosed with an aggressive form of leukemia at the prime of his life; a cancer that defied all standard treatments.

8 Nov 2019

New stem cell transplant lowers complications for patients with acute blood cancers

The discovery of the UM171 molecule, by Dr. Guy Sauvageau and Anne Marinier, made headlines in 2014 following an article in Science. Hailed by some as a revolution, even a miracle, in the field of blood stem cell transplantation, the UM171 molecule is delivering on its promise.

5 Nov 2019

NCCN publishes new clinical practice guidelines for hematopoietic cell transplantation

Today, the National Comprehensive Cancer Network published new NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation, also known as stem cell transplant or historically as bone marrow transplant.

30 Oct 2019

Graft Versus Host Disease

Overview

Types of Graft Versus Host Disease (GVHD)

Symptoms and Diagnosis of Graft Versus Host Disease (GVHD)

Treatment of Graft Versus Host Disease (GVHD)

Feature Articles

Causes and Risk Factors of Graft Versus Host Disease (GVHD)

Preventing Graft Versus Host Disease (GVHD)

Research into Graft Versus Host Disease (GVHD)

Graft Versus Host Disease Research

Latest Graft Versus Host Disease News and Research

'Humanized' mouse model beats current approaches for finding the best organ donor

Researchers conduct first-in-man clinical trial for new stem cell technology

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

Researchers develop an effective strategy to fight against chronic myelomonocytic leukemia

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Immune mechanism responsible for adverse inflammatory reactions after stem cell transplant identified

New Independent Research Organization status awarded to Anthony Nolan and ANRI

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

Umbilical cord blood safely and effectively treats children with rare genetic disorders

Ruxolitinib shows promise in severe COVID-19

Dana-Farber launches clinical test of blood cancer drug in COVID-19 patients

Harmful genetic mutations in healthy donors' stem cells may create problems in AML patients

Temperature fluctuations could give early indications of graft-versus-host disease

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

Adding venetoclax to transplant conditioning regimen shows promise in patients with myeloid cancers

Adding post-transplant chemotherapy to standard treatment improves remission of allogeneic transplant patients

A major step toward preventing GvHD in patients receiving bone marrow transplants

New stem cell technology gives new hope for high-risk leukemia patients

New stem cell transplant lowers complications for patients with acute blood cancers

NCCN publishes new clinical practice guidelines for hematopoietic cell transplantation

How has COVID-19 Impacted our Economy?

Using lab-grown stomachs to shed light on the symptoms of COVID-19

Developing a 'Fingerprint' test that could diagnose Alzheimer’s early

Graft Versus Host Disease

Overview

Feature Articles

Causes and Risk Factors of Graft Versus Host Disease (GVHD)

Preventing Graft Versus Host Disease (GVHD)

Research into Graft Versus Host Disease (GVHD)

Graft Versus Host Disease Research

Latest Graft Versus Host Disease News and Research

Newsletters you may be interested in